31 results on '"Hendriks, L."'
Search Results
2. P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel
3. OA06.05 Consensual Definition of Stage III NSCLC Resectability: EORTC-Lung Cancer Group Initiative with Other Scientific Societies
4. 72P Association of receptor activator of nuclear factor kappa-B ligand (RANKL) and epidermal growth factor receptor (EGFR) gene expression with bone metastases (mets) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC)
5. EP14.01-014 Risk Factors for Brain Metastasis in Patients with Small Cell Lung Cancer: A Systematic Review and Meta-analysis
6. P1.15-01 Differential Diagnosis of Pneumonitis in Metastatic NSCLC (Non-Small Cell Lung Cancer) Patients Receiving Immunotherapy With Radiomics
7. OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)
8. P63.12 Radiotherapy for Small Cell Lung Cancer in Current Clinical Practice Guidelines
9. MA02.07 T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm+ NSCLC: Interim Analysis of a Phase II Trial
10. 30P Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008–2018: A nationwide population-based study from the Netherlands
11. P33.10 Identification of Long-Responders and Fast-Progressors under Immunotherapy Based on Early Monitoring of dNLR in Advanced NSCLC Patients
12. FP07.06 Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront.
13. ES09.05 Blood-based Biomarkers for Immunotherapy: Applications and Limitations
14. P1.04-31 Immunosenescence Correlates with Poor Outcome from PD-(L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
15. P1.01-120 Immune Checkpoint Inhibitors Versus Second Line Chemotherapy for Patients with Lung Cancer Refractory to First Line Chemotherapy
16. MA25.03 Tumor-Infiltrating Lymphocytes (TIL) and Outcomes with Immunotherapy (ICI) or Chemotherapy in Advanced NSCLC (aNSCLC) Patients
17. MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey
18. MA07.02 Early Change of dNLR Is Correlated with Outcomes in Advanced NSCLC Patients Treated with Immunotherapy
19. P3.12-11 Association of the Lung Immune Prognostic Index (LIPI) with Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients
20. P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status with Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients
21. P1.01-18 Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients
22. P1.01-07 Immune-Related Pneumonitis in NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy
23. MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts
24. MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC
25. MA25.03 Defining Oligometastatic Non-Small Cell Lung Cancer (NSCLC): An Evolving Multidisciplinary Expert Opinion
26. MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
27. OA07.07 PFS and OS Beyond 5 years of NSCLC Patients with Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)
28. 182P Real world anti-PD-L1 treatment (tx) outcomes in a multinational European non-small cell lung cancer (NSCLC) cohort with focus on toxicity (tox) and brain metastases (BM): Preliminary data from an EORTC young investigators lung cancer group collaborative analysis
29. 115PD Brain metastases (BM) development after chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC): Does the type of chemotherapy matter?
30. 445 Expression of wild-type and mutant presenilin-1 cDNA in non-neuronal and neuronal cells
31. 356 Clinical and pathological findings in a family with early onset Alzheimer's disease and cerebral haemorrhage linked to the β-amyloid precursor protein gene
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.